

COVID-19 and Other Infectious Diseases Situational Report in the ASEAN Region

ASEAN BioDiaspora Virtual Center (ABVC)

as of April 20, 2022



Canada



COVID-19: Highlights and Situation Overview

Global Update

- Worldwide, there have been over 505 million cases and over 6 million deaths attributed to COVID-19.
- The world demand for Pfizer's oral COVID-19 antiviral pill Paxlovid has been low due to complicated eligibility requirements and demands are also hindered by the perception that Omicron variant is less severe than other variants. Paxlovid has shown 90% reduction of hospitalization or deaths in high-risk patients who contracted COVID-19 in clinical trials. Thousands of COVID-19 patients still die every week, despite infections are far off their peak. Even amid recent rise of infections, Paxlovid supply outstripped demand in United States, United Kingdom, Japan, and South Korea, data from health ministries and Reuters interviews with doctors and pharmacists. Pfizer plans to produce up to 120 million pills of Paxlovid in 2022 and expects at least US\$22 billion in sales from contracts signed through early February. The United States, which agreed to buy up to 20 million pills this year, making it the largest buyer that costs US\$530 a course. Prices may vary by country. Pfizer is on schedule to produce 3.5 million courses reserved for US use by the end of April. Through the first half of April, US data shows it has distributed around 1.5 million courses and that pharmacies still have over 500,000 available. On the other hand, Paxlovid rollout in Asia has been slow, despite some countries hitting record infections recently. South Korea has only received enough Paxlovid to treat 624,000 COVID-19 patients as of April 17, and has only used one-third of its stock, according to the data of Korean government. Japan has limited the use of 2 million contracted Paxlovid courses to facilities with a track record of treating COVID-19. As of March of 2022, only less than 10,000 courses had been sent out, and 2,900 prescribed.
- South Korea expects more foreign tourists from US as the Asian country is now tagged as Level 1 travel destination by the US State Department, which is seen as a low safety and security risk. On a separate announcement, US Center for Disease Control and Prevention (CDC) also moved South Korea from Level 4 "Do not Travel" list to Level 3, only those unvaccinated are discouraged to travel on this level. South Korea recorded 118,504 new COVID-19 cases on April 18, bringing a total of 16,471,940, according to Korea Disease Control and Prevention Agency (KDCA). The health authorities believed that the cases have been declining following the resurgence driven by the spread of the highly contagious Omicron variant and its subvariant BA.2, which peaked in mid-March. South Korea has fully vaccinated a total of 44,527,909 or 86.8% of total population against COVID-19 and boosted 33,017,514 or 64.3% of the total population.
- Health ministry of Japan has formally approved the fourth foreign-developed COVID-19 vaccine, Novavax as the country sees signs of a resurgence led by a subvariant of fast-spreading Omicron. Novavax adds to the choices available in Japan and could appeal to those who are hesitant to get COVID-19 vaccine such as Pfizer, Moderna, and AstraZeneca. Novavax vaccines are expected to be inoculated as early as late May. Booster shots have been slow in Japan and less than 50% of the population were boosted of mainly mRNA vaccines from Pfizer and Moderna. AstraZeneca is rarely used due to public concern about reports of rare blood clots and is largely donated to vaccine-scarce Asian countries bilaterally or through a United Nations-backed program. 80% of elderly populations in Japan had been boosted. Japan has agreed to purchase 150 million doses of Novavax COVID-19 vaccine developed by the Maryland company, which could help to maintain stable vaccine supply in the country. Takeda Pharmaceutical Co., of Japan plans to locally manufacture 250 million doses annually to reduce reliance on foreign imports as the development of local vaccines have fallen behind.

Regional Update

- Indonesia: 99.2% of Indonesian population has COVID-19 antibodies obtained either from vaccinations or infections, Health Minister Budi Gunadi Sadikin said on April 18. The serology survey conducted was higher than 88.6% conducted earlier last December 2021. The survey was conducted ahead of an exodus of people living in urban areas, returning to their hometowns to celebrate Eid al-Fitr with families, locally known as mudik. It is expected that as many as 79.4 million people would embark on such trip. A total of 162,879,095 people have been fully vaccinated against COVID-19 and 31,348,872 have been boosted as of April 18.
- Laos: The National Taskforce Committee for COVID-19 Prevention and Control has urged the public to continue monitoring their health and always check for symptoms of coronavirus for seven days after the Lao New Year celebrations. Communicable Disease Control of Laos has observed numerous people have attended celebrations during the Lao New Year holidays but failed to follow health guidelines on COVID-19 prevention. Those who will test positive for COVID-19 but with no symptoms are advised to self-isolate for 10 days. Those COVID-19 cases who have symptoms, do not improve, and experience difficulty of breathing are advised to consult their physician immediately to get an assessment and possibly to be admitted to the hospital. Furthermore, high risk groups are advised to get vaccinated as soon as possible.
- Philippines: Five cities in Metro Manila record zero new COVID-19 cases on April 19 including Malabon City, Muntinlupa City, Navotas City, Pasig City, and Valenzuela City according to Octa. On the other hand, Pasay City recorded 24 new COVID-19 cases, most number within the National Capital Region (NCR), followed by Taguig City with 10 new cases, and City of Manila with nine. The Philippines recorded 158 new COVID-19 cases on April 19 according to the Department of Health (DOH). This is the lowest number of new COVID-19 cases reported for this year.
- Singapore: Health Sciences Authority (HSA) approved molnupiravir, second oral antiviral drug against COVID-19 on April 19. The drug was granted with interim authorization under the Pandemic Special Access Route (PSAR) for MSD's Lagevrio on April 19, in consultation with its Medicines Advisory Committee. Molnupiravir was authorized for treating mild to moderate COVID-19 cases aged 18 and above, those who are at risk of progressing to severe COVID-19 or hospitalization or both, and in whom "alternative COVID-19 treatment options are not clinically appropriate." In February, Singapore approved the use of Pfizer's Paxlovid pill for the treatment adult COVID-19 patients who are at risk of severe disease.

Vaccine Update

- Brunei: Health ministry urges parents to get their children vaccinated against COVID-19 after some have experienced health complications after being infected with the Omicron variant. Unlike earlier cases of infections, children did not show any symptoms, Minister of Health Dato Seri Setia Dr. Mohd Isham Jaafar said. With Omicron, children usually show symptoms and some may experience severe form of COVID-19. Health complications after being infected with COVID-19 were found among eight children aged two months to 10 years since February of 2022. The health risks due to COVID-19 should be considered for immunizing their children eligible to the program.
- Cambodia: A 10-day COVID-19 vaccination campaign will be launched by the Ministry of National Defence of Cambodia on April 20 to administer booster shots in Phnom Penh. In line with this program to protect more people against resurgence of the coronavirus, the

program also aims to identify cases of COVID-19 to different provinces targeted. The resumption of campaign came after the Khmer New Year holiday in the country, during which Prime Minister Hun Sen recommended that COVID-19 vaccination sites be set up on pagoda grounds and at resorts. Minister of Health Or Vandine said that the COVID-19 vaccination will be on-going even on holidays and celebrations because it is very important that they boosted every eligible member of the public. Vadine also urged the public to self-isolate if they become positive with COVID-19 test and/or exhibit symptoms to prevent the spread of virus among their family. As of April 19, Ministry of Health reported 14 new COVID-19 cases, 12 recoveries, and no new deaths.

- According to Malaysia's CovidNow website, a total of 487,728 children aged five to 11 or 13.7% of the child population in the country have been fully vaccinated under the COVID-19 National Immunisation Programme for Children (PICKids) as of April 19. A total of 1,425,865 children in the same age group or 40.1% have received at least one dose of the vaccine. For adolescents aged 12 to 17, a total of 2,877,332 individuals or 92.5% of the group have completed the vaccination, while 2,978,531 or 95.8 per cent have received at least one dose of the vaccine. As for the adult population, a total of 15,985,545 individuals or 67.9% have received the booster dose, 22,961,980 or 97.6% have completed both doses, while 23,238,874 or 98.8% have received at least one dose of the vaccine. On April 19, a total of 47,612 doses of the vaccine were administered, with 35,398 as second doses, 4,635 booster doses and 7,579 as first doses, bringing the cumulative number of vaccine doses dispensed under the National COVID-19 Immunisation Programme (PICK) to 69,742,922. Meanwhile, according to the Health Ministry's GitHub portal, 12 deaths due to COVID-19 were reported on April 19, with Perak recording the highest number at five cases, followed by Johor with three cases.

Travel Advisories (new update/s)

- Indonesia: COVID-19 Task Force has officially removed the antigen test travel requirement for fully-vaccinated children and adolescents aged six to 17. The announcement is stated in the Addendum to the COVID-19 Task Force's Circular (SE) No. 16 of 2022 concerning domestic travel during the COVID-19 pandemic which takes effect immediately. Children below age six must be accompanied by a fully vaccinated companion who has passed the COVID-19 test. 6213819

Cases and Deaths as of 20 April 2022

- As of 20 April 2022 (2PM, GMT+8), worldwide, there were **505,532,344** confirmed cases, including **6,217,638*** deaths. Globally, Case Fatality Rate (CFR) was **1.2**.
- 56,257,798 confirmed cases** of COVID-19 have been reported in the **ASEAN +3** countries including **30,933,385 cases** in the ASEAN region and **25,324,413 cases** in the PLUS THREE countries, with CFR of **0.7**.

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CASE FATALITY RATE	CUMULATIVE CASES/ 100,000	NUMBER OF TESTS LAST 14 DAYS/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED / 100
ASEAN REGION	Brunei	10 Mar 20	19-Apr-22	140,364	182	218	-	0.2%	32,395		412,058	405,414	267,071	91.82
	Cambodia	27 Jan 20	19-Apr-22	136,090	14	3,055	-	2.2%	825	97	14,855,108	14,110,905	9,328,306	83.27
	Indonesia	02 Mar 20	19-Apr-22	6,041,269	837	155,937	34	2.6%	2,232	-	198,248,066	162,879,095	31,860,639	58.94
	Lao PDR	24 Mar 20	19-Apr-22	201,460	958	727	5	0.4%	2,810	132	5,734,044	4,736,698		64.19
	Malaysia	25 Jan 20	19-Apr-22	4,402,234	6,069	35,449	12	0.8%	13,779	2,035	27,635,355	26,289,727	15,980,555	80.21
	Myanmar	23 Mar 20	19-Apr-22	612,658	56	19,434	-	3.2%	1,134	295	28,522,949	22,337,339		40.76
	Philippines	30 Jan 20	19-Apr-22	3,683,367	156	59,982	6	1.6%	3,407	56	70,173,137	66,979,873	12,687,684	60.32
	Singapore	23 Jan 20	19-Apr-22	1,162,780	2,480	1,316	-	0.1%	20,387		5,010,668	4,977,613	3,943,988	91.27
	Thailand	13 Jan 20	19-Apr-22	4,063,844	16,891	27,138	129	0.7%	5,837	-	55,870,078	50,566,756	24,912,858	72.29
	Vietnam	23 Jan 20	19-Apr-22	10,489,319	13,500	42,975	18	0.4%	10,874	1,153	79,947,189	77,754,108	45,443,077	79.2
ASEAN COUNTRIES				30,933,385	41,143	346,231	204	1.1%			486,408,652	431,037,528	144,424,178	
ASEAN PLUS THREE	South Korea	20-Jan-20	19-Apr-22	16,471,940	118,445	21,354	130	0.1%	31,855	6,245	45,013,799	44,527,909	33,017,514	86.79
	Japan	16-Jan-20	19-Apr-22	7,427,292	40,987	28,934	52	0.4%	5,882	1,154	102,955,657	101,173,476	61,672,583	80.26
	China	31-Dec-19	17-Apr-22	1,425,181	5,643	14,680	26	1.0%	16,162	2,222	1,306,921,343	1,271,797,218	749,097,416	81.1
	PLUS THREE COUNTRIES				25,324,413	165,075	64,968	208	0.3%			1,454,890,799	1,417,498,603	843,787,513
ASEAN +3				56,257,798	206,218	411,199	412	0.7%			1,941,299,451	1,848,536,131	988,211,691	


- 449,274,546 confirmed cases** of COVID-19 have been reported in **5 continents** (other than ASEAN +3 countries):

CONTINENT	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CASE FATALITY RATE	CUMULATIVE CASES/ 100,000	NUMBER OF TESTS LAST 14 DAYS/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED
AFRICA	11,827,583	1,617	253,419	16	1.1	203,865	5,455	291,735,058	221,842,338	20,161,830
AMERICAS	153,578,976	8,725	2,732,504	38	0.8	880,130	32,513	794,715,886	697,687,559	294,704,556
ASIA PACIFIC	70,542,969	68,431	729,267	54	0.2	300,822	15,841	1,395,784,864	1,202,827,825	107,137,515
EUROPE	192,638,799	421,330	1,858,820	1,693	0.6	1,707,647	195,680	554,469,015	526,664,033	300,271,003
MIDDLE EAST	20,686,219	7,530	232,429	30	0.3	187,785	53,354	140,506,423	125,641,641	54,101,794
TOTAL	449,274,546	507,633	5,806,439	1,831	1.3%			3,177,211,246	2,774,663,396	776,376,698

*Correction on the death reported on April 18, 2022: Total deaths should be **6,213,819** and not 6,231,819.


COVID-19 Epi curve among ASEAN Countries:

From January 1, 2021 to April 19, 2022




COVID-19 Vaccination Status

as of 19 April 2022



COVID-19 Outlook Assessment

as of 17 April 2022

 ASEAN MEMBER STATE	REQUIREMENT							
	At least 80% of the high-risk population has been vaccinated with at least one dose of a COVID-19 vaccine.		At least 65% of the total population has a level of immunity to COVID-19; either recovered from COVID-19 or have been vaccinated with at least one dose of a COVID-19 vaccine.		Case levels are generally low (a 7-day rolling average number of daily new cases that is <10 cases per 100,000, with each day's past-14-day test positivity is consistently <5%).		Government Policy on containment and health (strictness and comprehensiveness in COVID-19 related government policies)	
	% of High risk population fully vaccinated	Population vaccinated/day (7-day average)	% of Total population fully vaccinated / boosted	Population vaccinated/day (7-day average)	Daily cases/100,000	Test positivity last 14 days	Containment and health index score - Oxford COVID-19 Government Response Tracker (OxCGRT)	Change over the past 30 days
Brunei	≥90.0	Unknown	≥90.0/60.5	Unknown	45.20	Unknown	67.9/100	0.0
Cambodia	≥90.0	0%/day	89.5/54.9	0.02%/day	0.10	2.5	37.5/100	0.0
Indonesia	≥90.0	0%/day	62.3/11.3	0.08%/day	0.36	Unknown	55.7/100	0.0
Lao PDR	≥90.0	0%/day	70.1/ND	0.32%/day	8.71	100	78.3/100	0.0
Malaysia	≥90.0	0%/day	80.6/48.7	0.13%/day	24.80	13.6	58.0/100	0.0
Myanmar	≥90.0	0%/day	42.2/ND	Unknown	0.06	0.5	77.7/100	0.0
Philippines	≥90.0	0%/day	64.5/11.2	0.13%/day	0.20	1.6	82.4/100	0.0
Singapore	≥90.0	0%/day	88.2/71.8	0.03%/day	49.42	Unknown	74.4/100	0.0
Thailand	≥90.0	0%/day	73.4/35.5	0.01%/day	28.95	44	53.3/100	0.0
Vietnam	88.0	0.06%/day	83.9/46.3	Unknown	34.70	57.6	71.4/100	0.0

Infectious Diseases other than COVID-19 in ASEAN+3 Countries

From February 20, 2022 to April 20, 2022

ASEAN +3

Infectious diseases other than COVID-19 in ASEAN + 3 countries, February 20, 2022 – April 20, 2022

Hongkong
Legionellosis 11 cases

Hong Kong

Powered by Bing
© Microsoft, NavInfo

China
HPAI (H5N6) 11 cases 3 deaths
Avian influenza (H9N2) 8 cases

Taiwan
Leptospirosis 9 cases
Mumps 48 cases
Hepatitis A 79 cases
Scrub typhus 24 cases
Hantavirus 1 case
Listeriosis 34 cases 3 deaths
Q fever 1 case

Philippines
Dengue 5,360 cases 12 deaths
Leptospirosis 37 cases 4 deaths
HFMD 60 cases
Measles 45 cases

Indonesia
Dengue 17,856 cases 185 deaths
Malaria 306 cases
Leptospirosis 9 cases 2 deaths
Rabies 1 case 1 death
Diphtheria 2 cases 1 death

Malaysia
Dengue 5,973 cases
3 deaths
Chikungunya 187 cases

Cambodia
Dengue 179 cases 1 death
Avian influenza (H9N2) 1 case
Diphtheria 2 cases 1 death

Thailand
Dengue 904 cases 1 death
Chikungunya 39 cases

Lao PDR
Dengue 51 cases

Vietnam
Dengue 4,368 cases 2 deaths

Singapore
Dengue 3,368 cases
Malaria 1 case
Leptospirosis 2 cases
Typhoid 6 cases
Paratyphoid 1 case
Mumps 14 cases
Hepatitis A 4 cases
Cholera 5 cases
Hepatitis E 3 cases
Meloidosis 5 cases
Legionellosis 1 cases

Singapore

Powered by Bing
© Microsoft, TomTom

Powered by Bing
© GeoNames, Microsoft, NavInfo, TomTom



Report generated by
ASEAN Biodiaspora Virtual Center (ABVC)
in collaboration with **Bluedot Inc.**
Email: support@biodiaspora.org

